NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

Reported by Yahoo Finance · Published 23 Sep 2026, 9:20 AM MYT (1 d ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

Brooklyn man sent to prison for 12 years for stealing $16M in a Coinbase phishing scheme 1 hr ago Qualcomm, Apple extend licensing agreement for chips 1 hr ago Litecoin token has its moment as network activity booms 1 hr ago Live updates: Bitcoin continues lower as bond yields take center stage 1 hr ago The stock market is ‘priced for perfection.’ Here’s what could drive a nearly 20% slump for the S&P 500 next year. 1 hr ago Pasqal ramps up growth plans after Nasdaq listing strengthens balance sheet 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

Summary

More in Markets

The stock market is ‘priced for perfection.’ Here’s what could drive a nearly 20% slump for the S&P 500 next year.

As the Trump-Xi meetings unfold, investors should watch for this hidden AI trade

Black Monday’s stock-market warning signal came from the bond market, and it’s back, says Wall Street veteran

China confirms first AI talks with U.S. have taken place, hints at trade truce extension

‘We made a bad, bad decision’: I learned the hard way how to manage my aging father’s money

Meta gets price-target boost as JPMorgan says Muse agent has potential to become the top AI application since ChatGPT